Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 11 04:00PM ET
0.6000
Dollar change
+0.0150
Percentage change
2.56
%
Index- P/E- EPS (ttm)-29.88 Insider Own5.23% Shs Outstand8.75M Perf Week-14.29%
Market Cap5.03M Forward P/E- EPS next Y- Insider Trans1.25% Shs Float8.29M Perf Month-16.08%
Income-11.38M PEG- EPS next Q-0.37 Inst Own0.02% Short Float0.59% Perf Quarter-93.99%
Sales0.00M P/S- EPS this Y- Inst Trans1.16% Short Ratio0.03 Perf Half Y-84.73%
Book/sh5.90 P/B0.10 EPS next Y- ROA-32.86% Short Interest0.05M Perf Year-96.70%
Cash/sh0.21 P/C2.79 EPS next 5Y- ROE-103.25% 52W Range0.53 - 22.36 Perf YTD-95.36%
Dividend Est.- P/FCF- EPS past 5Y66.05% ROI-100.21% 52W High-97.32% Beta0.57
Dividend TTM- Quick Ratio0.23 Sales past 5Y-37.79% Gross Margin- 52W Low13.21% ATR (14)0.18
Dividend Ex-Date- Current Ratio0.23 EPS Y/Y TTM93.48% Oper. Margin0.00% RSI (14)27.58 Volatility12.28% 14.52%
Employees15 Debt/Eq0.37 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q29.07% Payout- Rel Volume0.17 Prev Close0.58
Sales Surprise- EPS Surprise-157.83% Sales Q/Q- EarningsAug 20 AMC Avg Volume1.66M Price0.60
SMA20-22.48% SMA50-65.69% SMA200-87.92% Trades Volume283,710 Change2.56%
Date Action Analyst Rating Change Price Target Change
Jun-26-20Initiated Ladenburg Thalmann Buy $12.25
Nov-04-24 08:00AM
Oct-30-24 08:00AM
Oct-24-24 08:26AM
Oct-23-24 08:00AM
Oct-21-24 08:00AM
08:15AM Loading…
Oct-17-24 08:15AM
Oct-09-24 08:00AM
Sep-30-24 08:15AM
Sep-26-24 04:05PM
Sep-25-24 08:15AM
Sep-04-24 08:00AM
Aug-20-24 04:05PM
Aug-14-24 04:05PM
Jul-26-24 07:36AM
Jul-25-24 08:00AM
04:05PM Loading…
Jul-22-24 04:05PM
May-24-24 07:16AM
May-07-24 08:00AM
Apr-18-24 08:00AM
Apr-17-24 08:00AM
06:52AM
Apr-08-24 04:48PM
Feb-01-24 08:00AM
Jan-31-24 08:00AM
Jan-26-24 09:20AM
Jan-25-24 08:30AM
Jan-18-24 09:00AM
Jan-17-24 08:00AM
Jan-02-24 04:05PM
Dec-19-23 09:30AM
08:00AM Loading…
Dec-18-23 08:00AM
Nov-16-23 08:00AM
Nov-14-23 08:55AM
Nov-09-23 04:15PM
Nov-08-23 08:00AM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Oct-03-23 08:00AM
Sep-21-23 09:35AM
Aug-25-23 07:20AM
Aug-23-23 08:00AM
Aug-16-23 09:00AM
Aug-07-23 04:05PM
Jul-25-23 09:25AM
Jul-18-23 09:00AM
Jul-14-23 09:00AM
Jun-27-23 08:00AM
Jun-12-23 08:00AM
Jun-05-23 08:00AM
May-15-23 04:30PM
May-11-23 12:20PM
Apr-27-23 08:00AM
Apr-24-23 04:01PM
Apr-20-23 08:30AM
Apr-17-23 08:00AM
Apr-03-23 07:35AM
Mar-13-23 08:00AM
Mar-06-23 08:00AM
Feb-28-23 08:00AM
Feb-27-23 08:00AM
Feb-24-23 08:00AM
Feb-23-23 12:00PM
Jan-20-23 08:37AM
Dec-05-22 07:30AM
Nov-18-22 12:00PM
Nov-14-22 07:30AM
Oct-25-22 08:00AM
Oct-06-22 06:50AM
Sep-29-22 07:45AM
Sep-28-22 04:05PM
Sep-26-22 08:00AM
Sep-21-22 04:05PM
Sep-06-22 04:05PM
Aug-24-22 02:59PM
Aug-23-22 08:00AM
Aug-11-22 04:05PM
Jun-29-22 08:00AM
May-23-22 10:12AM
May-16-22 07:00AM
May-05-22 04:05PM
Apr-20-22 04:05PM
07:00AM
Mar-31-22 04:05PM
03:26PM
07:05AM
Mar-22-22 01:47PM
07:30AM
Mar-15-22 12:06PM
07:00AM
Mar-10-22 08:00AM
Feb-01-22 02:36PM
07:30AM
Dec-15-21 08:00AM
Nov-22-21 04:59PM
08:00AM
Nov-10-21 04:05PM
Oct-26-21 10:33AM
08:51AM
Oct-25-21 07:30AM
Oct-20-21 07:36AM
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOOct 08 '24Buy0.915,4314,9428,638Oct 09 07:46 AM